HRT for Women: Benefits, Risks, and the Current Evidence

The short answer: For most healthy women under 60 or within 10 years of their last period, hormone therapy is the most effective treatment for hot flashes, night sweats, and other menopause symptoms, and its benefits generally outweigh its risks, according to the 2022 hormone therapy position statement of The Menopause Society. The headline scares from the early 2000s came from the Women’s Health Initiative, whose participants were, on average, in their sixties and much older than the women who actually start treatment today. Timing, dose, route and the type of hormone all matter, and the decision is individual, made with a clinician who knows your history.

Hormone replacement therapy (HRT), now more often called menopausal hormone therapy (MHT), has had one of the most turbulent reputations in modern medicine. For two decades many women avoided it, and many doctors hesitated to prescribe it, based on an interpretation of one large trial that later research has substantially revised. Here is what the current evidence actually says.

What HRT is, and what it does

Menopausal hormone therapy replaces the estrogen (and usually progesterone) that the ovaries stop producing around menopause. Estrogen is the active ingredient that relieves symptoms. Progesterone, or a synthetic progestogen, is added for any woman who still has her uterus, because estrogen on its own can overstimulate the uterine lining and raise the risk of endometrial cancer. Women who have had a hysterectomy can usually take estrogen alone.

Clinicians often shorten these two approaches to ET (estrogen therapy alone) and EPT (estrogen plus progestogen therapy). The hormone replacement therapy guide covers the clinical basics of each in more depth.

The strongest, most consistent benefit is relief of vasomotor symptoms, the medical term for hot flashes and night sweats. MHT is the most effective treatment available for these. It is also first-line for the genitourinary syndrome of menopause (vaginal dryness, discomfort, recurrent urinary symptoms), where low-dose vaginal estrogen works locally with very little absorption into the rest of the body. It prevents early postmenopausal bone loss and reduces fractures, and many women report better sleep, mood, and quality of life.

What symptoms does HRT treat?

Systemic hormone therapy treats the symptoms driven by falling estrogen during the menopause transition: hot flashes, night sweats, the sleep disruption that follows them, and the bone loss of the early postmenopausal years. Local vaginal estrogen treats atrophic vaginitis, now called the genitourinary syndrome of menopause, including dryness, painful sex and recurrent urinary symptoms. Mood changes, joint aches and brain fog often improve when sleep and hot flashes improve, though hormone therapy is not an approved treatment for depression or dementia.

What types of HRT are there?

Hormone therapy comes in several forms, and the route of delivery changes the risk profile as much as the hormone itself. The table below summarizes the main options available in the United States.

Are bioidentical hormones different?

Bioidentical hormones are chemically identical to the hormones the body makes. Estradiol and micronized progesterone are bioidentical and are available as FDA approved, standardized products that insurance often covers. Compounded bioidentical hormone therapy, including custom creams, troches and pellets, is not FDA approved, and a 2020 report from the National Academies of Sciences, Engineering, and Medicine found insufficient evidence to support its routine use. The Menopause Society and the American College of Obstetricians and Gynecologists (ACOG) both recommend FDA approved products for most women. The bioidentical hormone therapy explainer goes further into the difference.

The WHI study, and why it was misread

In 2002 the Women’s Health Initiative (WHI), a large randomized trial funded by the National Institutes of Health, stopped its estrogen-plus-progestin arm early after finding an increase in breast cancer risk. The principal results, published by Rossouw and colleagues in JAMA (2002), drew alarming news coverage, and prescriptions dropped sharply worldwide.

Two things were lost in that coverage. First, the absolute risk was small. The trial reported roughly eight additional breast cancer cases per 10,000 women per year in the combined-therapy group, a real but modest increase. Second, and more important, the average woman in the WHI was in her early-to-mid sixties, well past menopause, and the trial used a specific oral combination: conjugated equine estrogens plus medroxyprogesterone acetate. The results were generalized to all women, all ages, and all formulations, which the data did not support.

Later re-analyses of the WHI itself, along with subsequent research, painted a more nuanced picture. The estrogen-alone arm (for women who had had a hysterectomy) actually showed a neutral to slightly lower breast cancer risk. A long-term follow-up by Manson and colleagues in JAMA (2013) found that outcomes differed by age group, with younger women in the trial faring better than older ones. In 2025, US health authorities moved to revise the longstanding boxed warnings on hormone therapy products, reflecting this updated understanding. This is a genuine course correction, not a marketing claim.

The timing hypothesis

The most useful idea to come out of the reinterpretation is the timing hypothesis. It holds that when you start hormone therapy matters as much as whether you take it at all.

Women who begin MHT close to menopause, generally under age 60 or within 10 years of their last period, tend to have a favorable balance of benefits and risks, including potential benefits for heart and bone health. Women who begin a decade or more after menopause, or after age 60, face a less favorable balance because the underlying risks of heart disease, stroke, blood clots, and dementia are higher to begin with. This is the framework endorsed by the 2022 position statement of The Menopause Society (formerly the North American Menopause Society).

The ELITE trial, reported by Hodis and colleagues in the New England Journal of Medicine (2016), tested the idea directly. Oral estradiol slowed the progression of carotid artery thickening in women who started within 6 years of menopause, but not in women who started 10 or more years after.

An important caveat: hormone therapy is not prescribed to prevent heart disease. Cardiovascular prevention is not an approved indication. The point is that starting earlier does not carry the cardiovascular penalty that the original WHI headlines implied.

Risks, in proportion

Real risks exist, and they vary by formulation and how the hormone is delivered.

• Breast cancer: Combined estrogen-plus-progestogen therapy carries a small increased risk that grows with longer duration of use. Estrogen-alone therapy appears neutral to slightly protective in the WHI data.
• Blood clots and stroke: Oral estrogen, particularly conjugated equine estrogens, raises the risk of venous thromboembolism and stroke more than transdermal estradiol does. For women with clotting or cardiovascular risk factors, patches or gels are often preferred because they bypass the liver.
• Progestogen choice: The type of progestogen matters. Some data suggest micronized (body-identical) progesterone has a more favorable profile for clot and possibly breast risk than certain synthetic progestins, though research is still evolving here, so this should be discussed individually.
• Endometrial cancer: Unopposed systemic estrogen in a woman with a uterus raises the risk of endometrial cancer, which is why a progestogen is added. Any bleeding after menopause needs evaluation, and our page on postmenopausal bleeding explains why.
• Dementia after 65: The WHI Memory Study (Shumaker and colleagues, JAMA, 2003) found a higher dementia risk in women who started combined therapy at 65 or older, one reason hormone therapy is not started late for brain protection.

Common side effects in the first months include breast tenderness, bloating, headaches and irregular spotting. These often settle, and a change of dose, route or progestogen usually helps when they do not. The HRT side effects explainer covers them one by one.

Hormone therapy is generally not appropriate for women with a history of breast cancer, estrogen-sensitive cancers, unexplained vaginal bleeding, active liver disease, a prior blood clot or clotting disorder, or certain cardiovascular conditions. Any prescription MHT requires medical supervision and an individual assessment of your history.

Who it is for

The clearest candidates are women with bothersome hot flashes and night sweats who are under 60 or within 10 years of menopause and have no contraindications. Women whose main complaint is vaginal or urinary symptoms can often use low-dose local vaginal estrogen, which has a very low risk profile and is suitable for many women who cannot take systemic therapy. Women with early or premature menopause (before 45) are usually advised to use hormone therapy at least until the natural age of menopause, for bone, heart, and brain protection.

The same applies after surgical menopause, when removal of both ovaries brings on symptoms abruptly. Women in perimenopause can also start hormone therapy, since symptoms often peak in the years before the final period.

If you are weighing this decision, the symptoms you are experiencing are worth understanding in their own right. Our perimenopause guide covers the transition that often begins years before periods stop, and we have separate explainers on menopause and weight gain and menopause brain fog, two of the most common and least discussed effects.

What are the alternatives to HRT?

Women who cannot or prefer not to take estrogen have non-hormonal options for hot flashes. Fezolinetant, a neurokinin 3 receptor antagonist, was approved by the FDA in 2023 specifically for moderate to severe vasomotor symptoms. Low-dose paroxetine is FDA approved for the same use, and clinicians also prescribe other SSRIs, SNRIs and gabapentin off label.

These options are generally less effective than estrogen for hot flashes, and none of them protects bone. Cognitive behavioral therapy has supporting evidence for how bothersome hot flashes feel, while most herbal and over-the-counter menopause supplements have thin or inconsistent evidence behind them.

How to start HRT, and who prescribes it

HRT is a prescription treatment. Gynecologists, primary care physicians, nurse practitioners and physician assistants prescribe it, and some clinicians hold a menopause certification from The Menopause Society. Functional and integrative medicine clinics and dedicated hormone clinics also offer it, often as cash pay services, so ask whether a clinic uses FDA approved products or compounded ones before you book.

1. Track your symptoms for a few weeks: hot flashes, sleep, mood, cycle changes and any bleeding.
2. Bring your personal and family history of breast cancer, blood clots, stroke, heart disease and liver disease to the first visit.
3. Expect a blood pressure check and a review of your mammogram and cervical screening status. Blood hormone levels are usually not needed to diagnose menopause in women over 45.
4. Agree on a starting product, dose and route, then review symptoms and side effects after about three months.
5. Revisit the decision at least once a year as your age, health and goals change.

Our directory of HRT clinics lists providers by state and city. Listing order is not paid ranking, Featured slots are labeled and capped, Verified means the clinic completed credential checks rather than paid for the label, and the directory is free for patients. Inclusion is not an endorsement, so use the list to start a conversation, not to replace one. The menopause specialist explainer covers what to ask at a first appointment.

Frequently asked questions

Is HRT safe?

For most healthy women who start within 10 years of menopause or before age 60, the benefits of hormone therapy generally outweigh the risks for symptom relief and bone protection, according to The Menopause Society’s 2022 position statement. Safety depends on your age, time since menopause, personal and family medical history, and the specific formulation and route. It is not appropriate for everyone, particularly women with a history of breast cancer or blood clots, which is why it requires an individual assessment with a clinician.

Does HRT cause breast cancer?

Combined estrogen-plus-progestogen therapy is associated with a small increase in breast cancer risk that rises with longer use, on the order of a few extra cases per 10,000 women per year in the WHI data. Estrogen-alone therapy, used by women without a uterus, appeared neutral to slightly protective. The increase is real but modest, and it should be weighed against the benefits and against other factors that affect breast cancer risk, such as alcohol and body weight.

What is the difference between a patch and a pill?

A patch delivers estradiol through the skin, while a pill is swallowed and passes through the liver first. That first pass through the liver raises the risk of blood clots and stroke somewhat, so oral estrogen carries a higher clot risk than transdermal estrogen. Patches, gels and sprays bypass the liver. For women with cardiovascular or clotting risk factors, migraine or high triglycerides, clinicians often prefer the transdermal route. Both relieve hot flashes about equally well.

How long can you stay on HRT?

There is no arbitrary stop date for hormone therapy. Current guidance from The Menopause Society moved away from using the lowest dose for the shortest time as a blanket rule. Duration is individualized and reviewed at least yearly with your clinician, based on ongoing symptoms, risks and goals. Many women use it for several years, and some continue past 60 or 65 when the benefits still outweigh the risks. Symptoms can return after stopping, whether you taper or stop at once.

Can you start HRT during perimenopause?

Yes, women can start hormone therapy during perimenopause, the years of irregular cycles before the final period, when hot flashes, night sweats and sleep problems are often at their worst. Because the ovaries still produce hormones unpredictably, clinicians sometimes use a low-dose birth control pill or a progestogen IUD with added estrogen instead of standard menopausal doses. Starting in perimenopause falls within the favorable window of the timing hypothesis, so the benefit and risk balance is generally good for healthy women.

Does HRT cause weight gain?

Hormone therapy does not cause weight gain in clinical trials, including the WHI. Midlife weight gain is common because of aging, lower muscle mass, sleep loss and falling activity levels, and the drop in estrogen shifts fat toward the abdomen. Some women notice bloating or fluid retention in the first months of treatment, which usually settles or improves with a change of dose or route. Strength training, sleep and diet remain the main tools for managing weight after menopause.

Related reading

• Perimenopause: a complete guide
• Menopause and weight gain
• Menopause brain fog
• Menopause HRT guide
• Menopause treatment options

This article is for education, not medical advice. Hormone therapy is a prescription treatment that requires individual assessment and medical supervision. Talk with a qualified clinician about your own history before starting, changing, or stopping any treatment.